Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy

Nature Reviews Urology

Volumn 13, Issue 1, 2016, Pages 47-60

  Narayanan, Sujata ^a   Srinivas, Sandy ^a   Feldman, David ^b  

^a STANFORD CANCER INSTITUTE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ANDROGEN; ANDROGEN RECEPTOR; APALUTAMIDE; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; DEXAMETHASONE; ENZALUTAMIDE; EPLERENONE; FLUTAMIDE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; HYDROCORTISONE; MESSENGER RNA; MIFEPRISTONE; MITOXANTRONE; NILUTAMIDE; PREDNISONE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; SOMATOMEDIN C; SPIRONOLACTONE; TESTOSTERONE; TRIAMCINOLONE; ZOLEDRONIC ACID; ANTIANDROGEN;

ADDISON DISEASE; ANDROGEN DEPRIVATION THERAPY; ANDROGEN SYNTHESIS; ANEMIA; ANTIANDROGEN THERAPY; BACKACHE; BONE METASTASIS; CANCER RESISTANCE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CUSHING SYNDROME; EVENING DOSAGE; FATIGUE; FRACTURE; HEMATOLOGIC MALIGNANCY; HUMAN; MORNING DOSAGE; MUSCLE WEAKNESS; OSTEOPOROSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SPINAL CORD COMPRESSION; UPREGULATION; ANIMAL; DRUG INTERACTION; MALE; METABOLISM; PHYSIOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SIGNAL TRANSDUCTION;

ANDROGEN ANTAGONISTS; ANDROGENS; ANIMALS; DRUG INTERACTIONS; GLUCOCORTICOIDS; HUMANS; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SIGNAL TRANSDUCTION;

EID: 84953368394     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2015.254     Document Type: Review

References (144)

1. Scher, H. I., et al. Association of baseline corticosteroid with outcomes in a multivariate analysis of the phase 3 affirm study of enzalutamide (enza), an androgen receptor signaling inhibitor (ARSI) [abstract]. Ann. Oncol. 23, 297 (2012).
2. Scher, H. I., et al. Impact of on-study corticosteroid use on efficacy and safety in the phase III trial of enzalutamide (ENZA), an androgen receptor inhibitor [abstract]. J. Clin. Oncol. 31, S6 (2013).
3. Arora, V. K., et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155,1309-1322 (2013).
4. Montgomery, B., et al. Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU AA 301. Eur. Urol. 67, 866-873 (2015).
5. Montgomery, B., Cheng, H. H., Drechsler, J., & Mostaghel E. A. Glucocorticoids and prostate cancer treatment: friend or foe?. Asian J. Androl. 16, 354-358 (2014).
6. Titus, M A., et al. 5a reductase type 3 enzyme in benign and malignant prostate. Prostate 74 235-249 2014
7. Mangelsdorf, D. J., et al. The nuclear receptor superfamily: the second decade. Cell 83, 835-839 (1995).
8. Gelmann, E. P. Molecular biology of the androgen receptor. J. Clin. Oncol. 20, 3001-3015 (2002).
9. Heinlein, C. A., & Chang, C. Androgen receptor in prostate cancer. Endocr. Rev. 25, 276-308, (2004).
10. Bolton, E. C., et al. Cell-and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev. 21, 2005-2017 (2007).
11. Sahu, B., et al. Androgen receptor uses relaxed response element stringency for selective chromatin binding and transcriptional regulation in vivo. Nucleic Acids Res. 42, 4230-4240 (2014).
12. Helsen, C., et al. Structural basis for nuclear hormone receptor DNA binding. Mol. Cell. Endocrinol. 348, 411-417 (2012).
13. Sahu, B., et al. FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells. Cancer Res. 73, 1570-1580 (2013).
14. Pihlajamaa, P., et al. Tissue-specific pioneer factors associate with androgen receptor cistromes and transcription programs. EMBO J. 33, 312-326 (2014).
15. Zhao, Y., Tindall, D. J., & Huang, H. Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer. Int. J. Biol. Sci. 10, 614-619 (2014).
16. Krause, W. C., Shafi, A. A., Nakka, M., & Weigel N. L. Androgen receptor and its splice variant, AR V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells. Int. J. Biochem. Cell Biol. 54, 49-59 (2014).
17. Huggins, C., & Hodges, C. V. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J. Clin. 22, 232-240 (1972).
18. Tolis, G., et al. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc. Natl Acad. Sci. USA 79, 1658-1662 (1982).
19. Ferraldeschi, R., et al. Molecular pathways: Inhibiting steroid biosynthesis in prostate cancer. Clin. Cancer Res. 19, 3353-3359 (2013).
20. Feldman, B. J., & Feldman, D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 1, 34-45 (2001).
21. Lamont, K. R., & Tindall, D. J. Minireview: Alternative activation pathways for the androgen receptor in prostate cancer. Mol. Endocrinol. 25, 897-907 (2011).
22. Sharifi, N. Mechanisms of androgen receptor activation in castration-resistant prostate cancer. Endocrinology 154, 4010-4017 (2013).
23. Schrecengost, R., & Knudsen, K. E. Molecular pathogenesis and progression of prostate cancer. Semin. Oncol. 40, 244-258 (2013).
24. Chen, C. D., et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10, 33-39 (2004).
25. Antonarakis, E. S., et al. AR V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371, 1028-1038 (2014).
26. Geller, J., & Albert, J. D. Adrenal androgen blockade in relapsed prostate cancer. Eur. J. Cancer Clin. Oncol. 21, 1127-1131 (1985).
27. Helsen, C., et al. Androgen receptor antagonists for prostate cancer therapy. Endocr. Relat. Cancer 21, T105-T118 2014
28. Tran, C., et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324,787-790 (2009).
29. Feldman, D. Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis. Endocr. Rev. 7, 409-420 (1986).
30. Walsh, P. C. Re: contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression. J. Urol. 187, 912 (2012).
31. Vasaitis, T. S., Bruno, R. D., & Njar, V. C. CYP17 inhibitors for prostate cancer therapy. J. Steroid Biochem. Mol. Biol. 125, 23-31 (2011).
32. Ryan, C. J., et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138-148 (2013).
33. Mostaghel, E. A. Abiraterone in the treatment of metastatic castration-resistant prostate cancer. Cancer Manag. Res. 6, 39-51 (2014).
34. Ferraldeschi, R., & de Bono, J. Agents that target androgen synthesis in castration-resistant prostate cancer. Cancer J. 19, 34-42 (2013).
35. Fiandalo, M. V., Wilton, J., & Mohler, J. L. Roles for the backdoor pathway of androgen metabolism in prostate cancer response to castration and drug treatment. Int. J. Biol. Sci. 10, 596-601 (2014).
36. Colombel, M., Olsson, C. A., Ng, P. Y., & Buttyan, R. Hormone-regulated apoptosis results from reentry of differentiated prostate cells onto a defective cell cycle. Cancer Res. 52, 4313-4319 (1992).
37. Carver, B. S., et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19, 575-586 (2011).
38. Davies, H., et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002).
39. Cho, N. Y., et al. BRAF and KRAS mutations in prostatic adenocarcinoma. Int. J. Cancer 119, 1858-1862 2006
40. Grasso, C. S., et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239-243 (2012).
41. Visakorpi, T., et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 9, 401-406 (1995).
42. Taplin, M. E., et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 332, 1393-1398 (1995).
43. Chang, C. Y., Walther, P. J., & McDonnell, D. P. Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer. Cancer Res. 61, 8712-8717 (2001).
44. Culig, Z., et al. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol. Endocrinol. 7, 1541-1550 (1993).
45. Zhao, X. Y., et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat. Med. 6, 703-706 (2000).
46. Krishnan, A V., et al. A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer. Endocrinology 143 1889-1900 2002
47. Veldscholte, J., et al. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J. Steroid Biochem. Mol. Biol. 41, 665-669 (1992).
48. Joseph, J. D., et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN 509. Cancer Discov. 3 2013 1020-1029
49. Mostaghel, E. A., et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 67, 5033-5041 (2007).
50. Page, S. T., et al. Persistent intraprostatic androgen concentrations after medical castration in healthy men. J. Clin. Endocrinol. Metab. 91, 3850-3856 (2006).
51. Fiandalo, M. V., Wu, W., & Mohler, J. L. The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy. Curr. Drug Targets 14, 420-440 (2013).
52. Chang, K H., et al. A gain of function mutation in DHT synthesis in castration-resistant prostate cancer. Cell 154 1074-1084 2013
53. Efstathiou, E., et al. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur. Urol. 67, 53-60 (2015).
54. Clark, J. P., & Cooper, C. S. ETS gene fusions in prostate cancer. Nat. Rev. Urol. 6, 429-439, (2009).
55. Culig, Z., et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 54, 5474-5478, (1994).
56. Culig, Z., Steiner, H., Bartsch, G., & Hobisch A. Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours. Endocr. Relat. Cancer 12, 229-244 (2005).
57. Gelman, I. H. Androgen receptor activation in castration-recurrent prostate cancer: the role of Src-family and Ack1 tyrosine kinases. Int. J. Biol. Sci. 10, 620-626 (2014).
58. Dehm, S. M., Schmidt, L. J., Heemers, H. V., Vessella, R. L., & Tindall, D. J. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 68, 5469-5477 (2008).
59. Sun, S., et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J. Clin. Invest. 120, 2715-2730 (2010).
60. Sprenger, C. C., & Plymate, S. R. The link between androgen receptor splice variants and castration-resistant prostate cancer. Horm. Cancer 5, 207-217 (2014).
61. Nakazawa, M., Antonarakis, E. S., & Luo, J. Androgen receptor splice variants in the era of enzalutamide and abiraterone. Horm. Cancer 5, 265-273 (2014).
62. Lunardi, A., et al. A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat. Genet. 45, 747-755 (2013).
63. Roudier, M. P., et al. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum. Pathol. 34, 646-653 (2003).
64. Fraser, M., Berlin, A., Bristow, R. G., & van Der Kwast, T. Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer. Urol. Oncol. 33, 85-94 (2014).
65. Wyatt, A. W., et al. Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer. Genome Biol. 15, 426 (2014).
66. Barbieri, C. E., & Tomlins, S. A. The prostate cancer genome: perspectives and potential. Urol. Oncol. 32, e15-e22 (2014).
67. Claessens, F., et al. Emerging mechanisms of enzalutamide resistance in prostate cancer. Nat. Rev. Urol. 11, 712-716 (2014).
68. Sampieri K, Fodde R: Cancer stem cells and metastasis. Semin. Cancer Biol. 22, 187-193 (2012).
69. Castillo, V., Valenzuela, R., Huidobro, C., Contreras, H. R., & Castellon, E. A. Functional characteristics of cancer stem cells and their role in drug resistance of prostate cancer. Int. J. Oncol. 45, 985-994 (2014).
70. Li, P., Yang, R., & Gao, W. Q. Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer. Mol. Cancer 13, 55 (2014).
71. Nieto, C. M., Rider, L. C., & Cramer, S. D. Influence of stromal-epithelial interactions on androgen action. Endocr. Relat. Cancer 21, T147-T160 (2014).
72. Stewart, P. M., & Krone, N. P. In Williams textbook of endocrinology, 12th edn Ch. 15 (Eds Kronenberg, H., & Williams R. H.) 479-544 (Saunders/Elsevier, 2011)
73. Fakih, M., Johnson, C. S., & Trump, D. L. Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review. Urology 60, 553-561 (2002).
74. Kadmiel, M., & Cidlowski, J. A. Glucocorticoid receptor signaling in health and disease. Trends Pharmacol. Sci. 34, 518-530 (2013).
75. Vandevyver, S., Dejager, L., & Libert, C. Comprehensive overview of the structure and regulation of the glucocorticoid receptor. Endocr. Rev. 35, 671-693 (2014).
76. Grad, I., & Picard, D. The glucocorticoid responses are shaped by molecular chaperones. Mol. Cell. Endocrinol. 275, 2-12 (2007).
77. Pratt, W. B., Galigniana, M. D., Morishima, Y., & Murphy, P. J. Role of molecular chaperones in steroid receptor action. Essays Biochem. 40, 41-58 (2004).
78. De Bosscher, K., Vanden Berghe, W., & Haegeman, G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein 1: molecular mechanisms for gene repression. Endocr. Rev. 24, 488-522 (2003).
79. Kassi, E., & Moutsatsou, P. Glucocorticoid receptor signaling and prostate cancer. Cancer Lett. 302, 1-10 (2011).
80. Rhen, T., & Cidlowski, J. A. Antiinflammatory action of glucocorticoids new mechanisms for old drugs. N. Engl. J. Med. 353, 1711-1723 (2005).
81. Cato, A. C., Nestl, A., & Mink, S. Rapid actions of steroid receptors in cellular signaling pathways. Sci. STKE re9 (2002).
82. Rundlett, S. E., & Miesfeld, R. L. Quantitative differences in androgen and glucocorticoid receptor DNA binding properties contribute to receptor-selective transcriptional regulation. Mol. Cell. Endocrinol. 109, 1-10 (1995).
83. Coutinho, A. E., & Chapman, K. E. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol. Cell. Endocrinol. 335, 2-13 (2011).
84. Riccardi, C., et al. Glucocorticoid hormones in the regulation of cell death. Therapie 55, 165-169 (2000).
85. Miyoshi, H., Ohki, M., Nakagawa, T., & Honma, Y., et al. Glucocorticoids induce apoptosis in acute myeloid leukemia cell lines with A t(8;21) chromosome translocation. Leuk. Res. 21, 45-50 (1997).
86. Smets, L. A., Salomons, G., & van den Berg, J. Glucocorticoid induced apoptosis in leukemia. Adv. Exp. Med. Biol. 457, 607-614 (1999).
87. Dorff, T. B., & Crawford, E. D. Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer. Ann. Oncol. 24, 31-38 (2013).
88. Schwartz, J. R. Dexamethasone premedication for prophylaxis of taxane toxicities: can the doses be reduced when paclitaxel or docetaxel are given weekly?. J. Oncol. Pharm. Pract. 18, 250-256, (2012).
89. Tannock, I., et al. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J. Clin. Oncol. 7, 590-597 (1989).
90. Nishimura K., et al. Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 89, 2570-2576 (2000).
91. Storlie, J. A., et al. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer 76, 96-100 (1995).
92. Sartor, O., Weinberger, M., Moore, A., Li, A., & Figg, W. D. Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. Urology 52, 252-256 (1998).
93. Tannock, I. F., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. 14, 1756-1764 (1996).
94. Kantoff, P. W., et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J. Clin. Oncol. 17, 2506-2513 (1999).
95. Berry, W., Dakhil, S., Modiano, M., Gregurich, M., & Asmar, L. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J. Urol. 168, 2439-2443 (2002).
96. Moore, M. J., et al. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J. Clin. Oncol. 12, 689-694 (1994).
97. de Bono, J. S., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376, 1147-1154 (2010).
98. Tannock, I. F., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502-1512 (2004).
99. Lafeuille, M. H., et al. Real-world corticosteroid utilization patterns in patients with metastatic castration-resistant prostate cancer in 2 large US administrative claims databases. Am. Health Drug Benefits 6, 307-316 (2013).
100. Patel, S R., et al. A phase II randomized trial of megestrol acetate or dexamethasone in the treatment of hormonally refractory advanced carcinoma of the prostate. Cancer 66 1990 655-658
101. Kelly, W. K., et al. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J. Clin. Oncol. 13, 2208-2213 (1995).
102. Nishiyama, T., & Terunuma, M. Hormone/antihormone withdrawal and dexamethasone for hormone-refractory prostate cancer. Int. J. Urol. 5, 44-47 (1998).
103. Weitzman, A. L., et al. Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer. J. Urol. 163, 834-837 (2000).
104. Srinivas, S., Krishnan, A. V., Colocci, N., & Feldman, D. Phase II study evaluating oral triamcinolone in patients with androgen-independent prostate cancer. Urology 67, 1001-1006 (2006).
105. Fossa, S. D., et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J. Clin. Oncol. 19, 62-71 (2001).
106. de Bono, J. S., et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995-2005 (2011).
107. Saag, K. G., et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am. J. Med. 96, 115-123 (1994).
108. Chrousos, G. P., & Kino, T. Glucocorticoid signaling in the cell. Expanding clinical implications to complex human behavioral and somatic disorders. Ann. N. Y. Acad. Sci. 1179, 153-166, (2009).
109. Ferris, H. A., & Kahn, C. R. New mechanisms of glucocorticoid-induced insulin resistance: make no bones about it. J. Clin. Invest. 122, 3854-3857 (2012).
110. Henneicke, H., Gasparini, S. J., Brennan Speranza, T. C., Zhou, H., & Seibel M. J. Glucocorticoids and bone: local effects and systemic implications. Trends Endocrinol. Metab. 25, 197-211 (2014).
111. Skolarus, T. A., Caram, M. V., & Shahinian, V. B. Androgen deprivation associated bone disease. Curr. Opin. Urol. 24, 601-607 (2014).
112. Coleman, R., et al. Bone health in cancer patients: ESMO clinical practice guidelines. Ann. Oncol. S3 124-127 2014
113. Meulenbeld, H. J., et al. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic castration resistant prostate cancer (CRPC), the Netherlands Prostate Study (NePro). Eur. J. Cancer 48, 2993-3000 (2012).
114. Smith, M. R., et al. Denosumab and bone metastasis free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379, 39-46, (2012).
115. Wirth, M., et al. Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS). Eur. Urol. 67, 482-491 (2015).
116. Srinivas, S., & Colocci, N. Bone related events in high risk prostate cancer. J. Urol. 176, S50-S54 (2006).
117. Karagas, M. R., et al. Non-melanoma skin cancers and glucocorticoid therapy. Br. J. Cancer 85, 683-686 (2001).
118. Stuck, A. E., Minder, C. E., & Frey, F. J. Risk of infectious complications in patients taking glucocorticosteroids. Rev. Infect. Dis. 11, 954-963 (1989).
119. Starkman, M. N. Neuropsychiatric findings in Cushing syndrome and exogenous glucocorticoid administration. Endocrinol. Metab. Clin. North Am. 42, 477-488 (2013).
120. Scher, H. I., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187-1197 (2012).
121. Chism, D. D., De Silva, D., & Whang, Y. E. Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer. Expert Rev. Anticancer Ther. 14, 1369-1378 (2014).
122. Richards, J., et al. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res. 72, 2176-2182 (2012).
123. End, D., Molina, A., Todd, M., & Meyers, M. L. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res. 73, 2926 (2013).
124. Attard, G., et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J. Clin. Oncol. 27, 3742-3748 (2009).
125. Grigoryev, D. N., Long, B. J., Njar, V. C., & Brodie, A. H. Pregnenolone stimulates LNCaP prostate cancer cell growth via the mutated androgen receptor. J. Steroid Biochem. Mol. Biol. 75, 1-10, (2000).
126. Taplin, M. E., et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J. Clin. Oncol. 21, 2673-2678 (2003).
127. US National Library of Medicine ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01949337 (2015).
128. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01709734?term=NCT01709734&rank=1 (2015).
129. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02025010 (2015).
130. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01867710 (2015).
131. Lorente, D., et al. Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. Br. J. Cancer 111, 2248-2253 (2014).
132. Mostaghel, E. A., et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin. Cancer Res. 17, 5913-5925 (2011).
133. Balbas, M. D., et al. Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife 2, e00499 (2013).
134. Korpal, M., et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov. 3, 1030-1043 (2013).
135. Carreira, S., et al. Tumor clone dynamics in lethal prostate cancer. Sci. Transl. Med. 6, 254ra125 (2014).
136. Isikbay, M., et al. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm. Cancer 5, 72-89 (2014).
137. Tomlins, S. A., et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 66, 3396-4000 (2006).
138. Klokk, T. I., et al. Ligand-specific dynamics of the androgen receptor at its response element in living cells. Mol. Cell. Biol. 27, 1823-1843 (2007).
139. Tanaka H., et al. Monoclonal antibody targeting of N cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat. Med. 16, 1414-1420 (2010).
140. Choi, W., et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25, 152-165 (2014).
141. Hu, R., et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 69, 16-22 (2009).
142. Beer, T. M., et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 371, 424-433 (2014).
143. Han, K. S., et al. Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy. Br. J. Cancer 98, 86-90 (2008).
144. Kim, W., & Ryan, C. J. Quo vadis: Advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies. Cancer 121, 1 (2014).